Evidence map›Paper›PMID 41074062›Full record

ReviewCell communication and signaling : CCS2025

Integrating AI and RNA biomarkers in cancer: advances in diagnostics and targeted therapies.

Bashdar Mahmud Hussen, Snur Rasool Abdullah, Hazha Jamal Hidayat, Majid Samsami, Mohammad Taheri

Abstract readReview
In one paragraph

Review in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bashdar Mahmud HussenDepartment of Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Kurdistan Region, Iraq.
Snur Rasool AbdullahDepartment of Medical Laboratory Science, College of Health Sciences, Lebanese French University, Erbil, Kurdistan Region, Iraq.
Hazha Jamal HidayatDepartment of Biology, College of Education, Salahaddin University- Erbil, Erbil, Kurdistan Region, Iraq.
Majid SamsamiPhytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. samsamimd@gmail.com.
Mohammad TaheriInstitute of Human Genetics, Jena University Hospital, Jena, Germany. mohammad_823@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early detection and personalized treatment strategies are essential for enhancing patient outcomes, as cancer continues to be a significant cause of mortality on a global basis. In clinical practice, the identification and validation of reliable biomarkers for cancer diagnosis, prognosis, and therapeutic monitoring continue to present significant challenges. The present study explores the current state and applications of artificial intelligence-driven approaches in the identification and usage of RNA biomarkers for cancer diagnostics and therapeutics. In various aspects of cancer management, we explore the integration of machine learning and deep learning algorithms with a variety of RNA biomarker classes, such as circRNAs, miRNAs, and lncRNAs. Improved detection, subtype categorization, prognosis prediction, and treatment response monitoring are all possible due to AI-powered approaches that can efficiently analyse complex RNA expression patterns, discover novel biomarkers, and explain their functions in cancer biology. There are still many obstacles to overcome in the biomarker development, validation, and clinical application processes, despite the fact that RNA biomarkers hold great potential to transform cancer treatment by improving early detection and individualized therapy methods. Integrating AI with RNA biomarker research is a crucial strategy with enormous promise for precision oncology and better patient care all the way through the cancer spectrum, from risk prediction to recurrence management.

Indexed as

Artificial IntelligenceBiomarkers, TumorMolecular Targeted TherapyNeoplasmsRNAHumansBiomarkers, TumorRNAArtificial intelligence (AI)CancerRNA biomarkersTherapeutic target

Identifiers

PMID41074062
PMCPMC12512311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.